AG2R LA Mondiale Gestion D Actifs Has $2.13 Million Stock Position in Cencora, Inc. $COR

AG2R LA Mondiale Gestion D Actifs lifted its holdings in shares of Cencora, Inc. (NYSE:COR) by 8.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 7,102 shares of the company’s stock after purchasing an additional 543 shares during the quarter. AG2R LA Mondiale Gestion D Actifs’ holdings in Cencora were worth $2,130,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. Price T Rowe Associates Inc. MD increased its stake in shares of Cencora by 8.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 9,647,310 shares of the company’s stock worth $2,682,821,000 after purchasing an additional 787,858 shares during the last quarter. Wellington Management Group LLP boosted its holdings in shares of Cencora by 7.2% during the 1st quarter. Wellington Management Group LLP now owns 5,421,262 shares of the company’s stock worth $1,507,599,000 after buying an additional 363,402 shares during the period. Boston Partners boosted its holdings in shares of Cencora by 8.1% during the 1st quarter. Boston Partners now owns 5,411,193 shares of the company’s stock worth $1,505,984,000 after buying an additional 404,093 shares during the period. Invesco Ltd. boosted its holdings in shares of Cencora by 42.1% during the 1st quarter. Invesco Ltd. now owns 4,607,964 shares of the company’s stock worth $1,281,429,000 after buying an additional 1,364,433 shares during the period. Finally, Goldman Sachs Group Inc. boosted its holdings in shares of Cencora by 9.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,711,281 shares of the company’s stock worth $475,890,000 after buying an additional 154,311 shares during the period. Institutional investors and hedge funds own 97.52% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on COR. Wells Fargo & Company upped their price objective on shares of Cencora from $337.00 to $354.00 and gave the stock an “overweight” rating in a report on Wednesday, August 13th. Jefferies Financial Group upped their price objective on shares of Cencora from $275.00 to $300.00 and gave the stock a “hold” rating in a report on Monday, June 30th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Cencora in a report on Wednesday, October 8th. Mizuho increased their price target on shares of Cencora from $316.00 to $334.00 and gave the company an “outperform” rating in a report on Thursday, October 16th. Finally, Wall Street Zen downgraded shares of Cencora from a “buy” rating to a “hold” rating in a report on Saturday, October 11th. Nine equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $324.91.

Cencora Price Performance

Shares of Cencora stock opened at $333.02 on Friday. The company has a debt-to-equity ratio of 3.64, a current ratio of 0.90 and a quick ratio of 0.53. Cencora, Inc. has a fifty-two week low of $223.92 and a fifty-two week high of $334.34. The firm has a fifty day moving average price of $304.09 and a two-hundred day moving average price of $295.02. The company has a market cap of $64.56 billion, a PE ratio of 34.26, a price-to-earnings-growth ratio of 1.55 and a beta of 0.63.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, August 6th. The company reported $4.00 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.79 by $0.21. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The company had revenue of $80.66 billion during the quarter, compared to analysts’ expectations of $80.34 billion. During the same quarter in the prior year, the company posted $3.34 EPS. The business’s revenue was up 8.7% on a year-over-year basis. Analysts expect that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Friday, August 15th were paid a $0.55 dividend. The ex-dividend date was Friday, August 15th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.7%. Cencora’s dividend payout ratio is currently 22.63%.

Insider Transactions at Cencora

In related news, Chairman Steven H. Collis sold 31,350 shares of the stock in a transaction dated Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the completion of the sale, the chairman owned 305,913 shares in the company, valued at $88,671,942.18. This trade represents a 9.30% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Robert P. Mauch sold 5,097 shares of the stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the sale, the chief executive officer owned 37,940 shares of the company’s stock, valued at $12,398,792. This trade represents a 11.84% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 41,544 shares of company stock valued at $12,230,941 in the last quarter. 10.80% of the stock is currently owned by corporate insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.